Leukemia Clinical Trials in Atlanta

Showing 581-600 of 791 trials

PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib

NCT00548093

To assess the antitumor efficacy measured by the objective response rate of oral PF-00299804 taken daily, as single agent in patients with advanced NSCLC who failed at least one chemotherapy + erlotinib.

Carcinoma, Non Small Cell Lung

Pfizer66 participantsStarted Apr 2008

Duarte, California, United States • Pasadena, California, United States • South Pasadena, California, United States +16 more locations

COMPLETEDPHASE3< 1 mile

A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

NCT01539512

This Phase 3, randomized, double-blind, placebo-controlled study is to evaluate the effect of idelalisib in combination with rituximab on the onset, magnitude, and duration of tumor control in participants previously treated for chronic lymphocytic leukemia (CLL). Eligible patients will be randomized with a 1:1 ratio into 1 of the 2 treatment arms to receive either idelalisib plus rituximab or placebo plus rituximab. Participants who are tolerating primary study therapy but experience definitive CLL progression are eligible to receive active idelalisib therapy in the extension study, GS-US-312-0117.

Chronic Lymphocytic Leukemia

Gilead Sciences220 participantsStarted Apr 2012

Huntsville, Alabama, United States • Tucson, Arizona, United States • La Jolla, California, United States +69 more locations

PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib

A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Leukemia Trials in Other Cities

A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Persistent Pulmonary Hypertension of the Newborn (PPHN) Observational Study

Early Diagnosis of Candidiasis in Premature Infants

Antenatal Phenobarbital to Prevent Neonatal Intracranial Hemorrhage

Exosurf Neonatal and Survanta for Treatment of Respiratory Distress Syndrome

Immunogenicity of PCV-7 Vaccine in VLBW Infants

Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM

Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder

EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy

Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma

A Study for Patients With Acute Leukemia

LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer

BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML)

A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations

Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML

Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation

Comparability and Standardization of Controlled Allergen Challenge Facilities

Other Conditions in Atlanta